Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Ltd has announced that its equity shares have been admitted for trading on the National Stock Exchange of India (NSE) effective August 17, 2026. This follows permission granted by NSE under its regulations. The company's shares will trade under the symbol FREDUN with ISIN INE194R01017. Fredun Pharmaceuticals is already listed on the BSE, and this move expands its trading presence to another major stock exchange. The face value of the equity shares is Rs. 10/-.

Fredun Pharmaceuticals Ltd has confirmed no deviation or variation in the utilization of funds raised through a Preferential Issue for the quarter ended June 30, 2026. The company raised ₹111.53 Crore and has submitted a statement to this effect, approved by the Audit Committee and Board of Directors. A Monitoring Agency Report from CARE Ratings Limited, dated August 14, 2026, also indicates no deviation, although it noted observations on expenditure classification, documentation, fund routing, and reconciliation of unutilized proceeds. The company provided explanations for these classifications, considering them within the disclosed objects.

Fredun Pharmaceuticals Ltd has submitted a Monitoring Agency Report from Care Ratings Limited concerning the utilization of funds raised through a preferential allotment. The report, dated August 14, 2026, covers the quarters ended March 31, 2026, and June 30, 2026. The agency identified deviations in the use of proceeds, totaling ₹13.21 crore, for purposes not explicitly defined in the original objects, including loan EMIs, flat purchases, fund raise expenses, CSR activities, tax payments, PF payments, and R&D expenses without supporting documents. Discrepancies were also noted in the reported unutilized proceeds, with the company's figures differing from the agency's calculations.

Fredun Pharmaceuticals Limited announced its unaudited financial results for Q1 FY27, showcasing a significant year-on-year growth. Total income surged by 90.44% to ₹228.25 Cr from ₹119.86 Cr in Q1 FY26. EBITDA increased by 92.90% to ₹32.78 Cr, with EBITDA margin slightly improving by 18 basis points to 14.36%. Net profit saw a substantial rise of 94.63% to ₹13.17 Cr, and Net Profit margin improved by 12 basis points to 5.77%. Basic EPS grew by 66.71% to ₹23.89. The company also highlighted a bonus share allotment of 1.10 crore shares in a 2:1 ratio on July 17, 2026. Management expressed optimism about future growth driven by investments in branded portfolios, new categories, and manufacturing capabilities.

Fredun Pharmaceuticals Ltd announced that its Board of Directors, in a meeting held on August 5, 2026, has approved the un-audited financial results for the quarter ended June 30, 2026. The results were accompanied by a limited review report from the statutory auditors, M/s. R.H. Nisar & Co. The trading window for company insiders was closed from July 1, 2026, until 48 hours after the declaration of the board meeting's outcome. The board meeting commenced at 10:30 a.m. and concluded at 11:20 a.m.

Fredun Pharmaceuticals Ltd has announced that its Board of Directors will convene on August 5, 2026. The primary agenda item for this meeting is to consider and approve the Unaudited Financial Results for the first quarter ended June 30, 2026, for both standalone and consolidated statements. In line with SEBI regulations, the company has also informed that the trading window for its securities will be closed until 48 hours after the declaration of these financial results, to prevent insider trading.

Fredun Pharmaceuticals Limited announced the allotment of 11,025,380 fully paid-up Bonus Equity Shares. The allotment was made in a 2:1 ratio, meaning two new bonus shares for every one existing equity share held as of the record date, July 16, 2026. The face value of each share is ₹10. This bonus issue increases the company's issued and paid-up equity share capital from ₹5,51,26,900 (5,512,690 shares) to ₹16,53,80,700 (16,538,070 shares). The newly allotted bonus shares will rank pari-passu with existing equity shares, carrying identical rights including future dividends.

Fredun Pharmaceuticals Ltd has announced July 16, 2026, as the record date for its upcoming bonus equity share issue. The Board of Directors has approved a bonus ratio of 2:1, meaning shareholders will receive two fully paid-up equity shares of ₹10 each for every one existing equity share held. This issuance was previously approved by shareholders at the Annual General Meeting on June 30, 2026. The deemed date of allotment for these bonus shares will be the next working day following the record date (T+1). The new shares will rank pari passu with existing shares. Arrangements have also been made to adjust outstanding warrants to ensure holders receive equivalent economic benefits.

Fredun Pharmaceuticals Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be shut from Wednesday, July 1st, 2026, until 48 hours after the board meeting where the unaudited financial results for the quarter ended June 30th, 2026, will be considered, approved, and declared. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

Fredun Pharmaceuticals Ltd has announced that its 39th Annual General Meeting (AGM) will be held on Tuesday, June 30, 2026, at 9:00 am IST via Video Conferencing (VC) or Other Audio Visual Means (OAVM). The company is sending letters to members without registered email addresses, providing a weblink to access the Annual Report for FY 2025-26 and the AGM notice. This communication also serves as a reminder for shareholders holding physical securities to update their KYC details as per SEBI's latest circular, including PAN, address, mobile number, bank details, and nomination choice, to ensure continued eligibility for payments like dividends.